ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Teijin will pay about $13 million for a 50% stake in the Japanese implant company Nakashima Medical. Teijin expects that its cash injection and materials science expertise will enable Nakashima Medical to grow internationally and triple its sales to $84 million by 2020. At present, the firm is focused on the Japanese market for joint prostheses and trauma implants, where its share is about 3%.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X